FGF-1: From biology through engineering to potential medical applications

被引:12
作者
Zakrzewska, Malgorzata [1 ,2 ]
Marcinkowska, Ewa [1 ]
Wiedlocha, Antoni [2 ]
机构
[1] Univ Wroclaw, Fac Biotechnol, PL-50137 Wroclaw, Poland
[2] Univ Oslo, Rikshosp, Radium Hosp,,Ctr Canc Biomed, Ctr Med,Dept Biochem,Inst Canc Res, N-0027 Oslo, Norway
关键词
FGF-1; FGFR; recombinant protein; protein stability; activity; signaling; clinical application;
D O I
10.1080/10408360701713120
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Human fibroblast growth factor 1 (FGF-1) is one of the best characterized members of the FGF superfamily. FGF-1 is a powerful mitogen exhibiting strong action on numerous different cell types. It plays a role in various stages of development and morphogenesis, as well as in angiogenesis and wound healing processes. Engineering of FGFs can bring many advantages. Design and construction of different mutants can contribute to a better understanding of the mechanism of action of protein growth factors. Moreover, application of FGFs as recombinant polypeptides in the treatment of wound and fracture healing, cardiovascular diseases and neurodegenerative diseases seems to be a rational medical approach. However, low thermal stability and high sensitivity to proteases limit the potential pharmaceutical use of wild-type FGFs. Thus, advanced protein design techniques and recombinant protein production can help to obtain new variants of FGFs with radically increased thermodynamic stability, prolonged half-life and improved proteolytic resistance. Such studies can provide a good starting point to convert short-lived and/or sensitive growth factors to effective therapeutic proteins.
引用
收藏
页码:91 / 135
页数:45
相关论文
共 216 条
  • [51] PI3K: Downstream AKTion blocks apoptosis
    Franke, TF
    Kaplan, DR
    Cantley, LC
    [J]. CELL, 1997, 88 (04) : 435 - 437
  • [52] HUMAN PITUITARY GROWTH-HORMONE (HGH) THERAPY IN GROWTH-HORMONE DEFICIENCY
    FRASIER, SD
    [J]. ENDOCRINE REVIEWS, 1983, 4 (02) : 155 - 170
  • [53] Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation
    Freytes, CO
    Ratanatharathorn, V
    Taylor, C
    Abboud, C
    Chesser, N
    Restrepo, A
    Arango, J
    Odenheimer, D
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8318 - 8324
  • [54] MOLECULAR MECHANISMS OF ANGIOGENESIS - FIBROBLAST GROWTH-FACTOR SIGNAL-TRANSDUCTION
    FRIESEL, RE
    MACIAG, T
    [J]. FASEB JOURNAL, 1995, 9 (10) : 919 - 925
  • [55] Ghielli M, 1998, EXP NEPHROL, V6, P502
  • [56] THE COMPLETE AMINO-ACID-SEQUENCE OF HUMAN BRAIN-DERIVED ACIDIC FIBROBLAST GROWTH-FACTOR
    GIMENEZGALLEGO, G
    CONN, G
    HATCHER, VB
    THOMAS, KA
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 138 (02) : 611 - 617
  • [57] Gleizes PE, 1996, EUR J CELL BIOL, V71, P144
  • [58] Fibroblast growth factor homologous factors: Evolution, structure, and function
    Goldfarb, M
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (02) : 215 - 220
  • [59] Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing
    Goldstrohm, AC
    Greenleaf, AL
    Garcia-Blanco, MA
    [J]. GENE, 2001, 277 (1-2) : 31 - 47
  • [60] IRES-dependent regulation of FGF-2 mRNA translation in pathophysiological conditions in the mouse
    Gonzalez-Herrera, IG
    Prado-Lourenco, L
    Teshima-Kondo, S
    Kondo, K
    Cabon, F
    Arnal, JF
    Bayard, F
    Prats, AC
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2006, 34 : 17 - 21